66PAdapting a prescreening program to match molecular alterations in over 5, 000 patients' tumors with targeted agents and immunotherapies in early clinical trials over the last 8 years. (16th September 2018) - Aguilar, S; Vivancos, A; Nuciforo, P; Viaplana, C; Ruiz-Pace, F; Sanchez, E; Rodon, J; Tabernero, J; Garralda, E; Dienstmann, R